Variant (legacy)	HGVS	CFTR2 Classification	Variant Class	Variant Type	MONDO ID	MONDO Term	Allele Frequency	CFTR Modulator Treatment	Phenotype Notes
F508del	p.Phe508del	CF-causing	II (misfolding)	In-frame deletion	MONDO:0009061	Cystic fibrosis	~70% of CF alleles (87% in Denmark)	Yes — ETI (Trikafta/Kaftrio), Orkambi (homozygous), Symdeko, Alyftrek	Severe; pancreatic insufficient (PI); progressive lung disease; most common CF variant worldwide
F508del	p.Phe508del	CF-causing	II (misfolding)	In-frame deletion	MONDO:0010178	CBAVD from CFTR	~20% of CBAVD chromosomes	Not applicable (CBAVD)	Found as one allele in compound hets; typically in trans with 5T or mild variant
F508del	p.Phe508del	CF-causing	II (misfolding)	In-frame deletion	MONDO:7770003	CFRD	~70% (in CF context)	Yes (for underlying CF)	F508del/F508del homozygotes: ~80% develop CFRD by age 50; highest risk genotype
F508del	p.Phe508del	CF-causing	II (misfolding)	In-frame deletion	MONDO:7770005	CFLD	~70% (in CF context)	Yes (for underlying CF)	Any severe genotype increases baseline CFLD risk; SERPINA1 Z allele is main modifier (OR ~5)
F508del	p.Phe508del	CF-causing	II (misfolding)	In-frame deletion	MONDO:0005413	CF meconium ileus	~70% (in CF context)	Yes (for underlying CF)	Meconium ileus in ~15-20% of CF neonates; risk driven by modifier genes (SLC26A9, SLC6A14)
F508del	p.Phe508del	CF-causing	II (misfolding)	In-frame deletion	MONDO:0100627	CRMS/CFSPID	~70% (in CF context)	No (CRMS/CFSPID does not meet CF criteria)	When in trans with a VVCC variant (e.g., F508del/D1152H), may lead to CRMS/CFSPID designation
F508del	p.Phe508del	CF-causing	II (misfolding)	In-frame deletion	MONDO:7770004	CFTR-related disorder	~70% (in CF context)	Not applicable (CFTR-RD)	When in trans with mild/VVCC variant (e.g., F508del/R117H-5T), may cause single-organ CFTR-RD
F508del	p.Phe508del	CF-causing	II (misfolding)	In-frame deletion	MONDO:0008887	BESC1	Overrepresented in bronchiectasis patients	Unknown	Heterozygous F508del overrepresented; possibly oligogenic with ENaC variants
G542X	p.Gly542X	CF-causing	I (nonsense)	Nonsense	MONDO:0009061	Cystic fibrosis	~2.6%	No — no approved modulator (Class I nonsense; no protein produced)	Severe; PI; modulator-ineligible; enriched in Mediterranean/North Africa
G542X	p.Gly542X	CF-causing	I (nonsense)	Nonsense	MONDO:7770003	CFRD	~2.6% (in CF context)	No	High CFRD risk when homozygous or compound het with another severe variant
G542X	p.Gly542X	CF-causing	I (nonsense)	Nonsense	MONDO:0005413	CF meconium ileus	~2.6% (in CF context)	No	Higher meconium ileus risk reported with G542X
N1303K	p.Asn1303Lys	CF-causing	II (misfolding)	Missense	MONDO:0009061	Cystic fibrosis	~1.6%	Yes — ETI (Trikafta/Kaftrio), Alyftrek	Severe; PI; enriched in Mediterranean, Tunisia (17%)
G551D	p.Gly551Asp	CF-causing	III (gating)	Missense	MONDO:0009061	Cystic fibrosis	~1.5%	Yes — Ivacaftor (Kalydeco; first approved modulator), ETI, Alyftrek	Severe; PI; highly modulator-responsive; enriched in NW/Central Europe
W1282X	p.Trp1282X	CF-causing	I (nonsense)	Nonsense	MONDO:0009061	Cystic fibrosis	~1.0%	No — no approved modulator (Class I nonsense)	Severe; PI; modulator-ineligible; very high frequency in Ashkenazi Jewish populations
W1282X	p.Trp1282X	CF-causing	I (nonsense)	Nonsense	MONDO:7770003	CFRD	~1.0% (in CF context)	No	High CFRD risk when compound het with another severe variant
R553X	p.Arg553X	CF-causing	I (nonsense)	Nonsense	MONDO:0009061	Cystic fibrosis	~0.75%	No — no approved modulator (Class I nonsense)	Severe; PI; modulator-ineligible; enriched in Northern Europe
621+1G>T	c.489+1G>T	CF-causing	I (splice)	Splice-site	MONDO:0009061	Cystic fibrosis	~0.54%	No — no approved modulator (Class I splice-site)	Severe; PI; modulator-ineligible; enriched in Southern Europe (Greece ~6.4%)
1717-1G>A	c.1585-1G>A	CF-causing	I (splice)	Splice-site	MONDO:0009061	Cystic fibrosis	~0.5%	No — no approved modulator (Class I splice-site)	Severe; PI; modulator-ineligible
R117H	p.Arg117His	CF-causing (with 5T) / VVCC (with 7T)	IV (conductance)	Missense	MONDO:0009061	Cystic fibrosis	~0.3%	Yes — Ivacaftor (Kalydeco), ETI	CF-causing only when in cis with 5T allele; milder phenotype; often pancreatic sufficient (PS)
R117H	p.Arg117His	CF-causing (with 5T) / VVCC (with 7T)	IV (conductance)	Missense	MONDO:0010178	CBAVD from CFTR	~5-10% of CBAVD chromosomes	Not applicable (CBAVD)	Common in CBAVD compound hets (e.g., F508del/R117H-5T)
R117H	p.Arg117His	CF-causing (with 5T) / VVCC (with 7T)	IV (conductance)	Missense	MONDO:7770004	CFTR-related disorder	Overrepresented in CFTR-RD	Not applicable (CFTR-RD)	Found in pancreatitis and bronchiectasis with CFTR dysfunction
R117H	p.Arg117His	VVCC (with 7T)	IV (conductance)	Missense	MONDO:0100627	CRMS/CFSPID	Common in CRMS/CFSPID	No (CRMS/CFSPID)	R117H-7T is one of the most common VVCC variants triggering CRMS/CFSPID designation
R1162X	p.Arg1162X	CF-causing	I (nonsense)	Nonsense	MONDO:0009061	Cystic fibrosis	~0.3%	No — no approved modulator (Class I nonsense)	Severe; PI; modulator-ineligible
3849+10kbC>T	c.3718-2477C>T	CF-causing	V (splicing)	Deep intronic	MONDO:0009061	Cystic fibrosis	~0.2%	Yes — ETI (Trikafta/Kaftrio), Alyftrek	Milder; often PS; reduced CFTR quantity but some residual function
2789+5G>A	c.2657+5G>A	CF-causing	V (splicing)	Splice-site	MONDO:0009061	Cystic fibrosis	~0.2%	Yes — ETI (Trikafta/Kaftrio), Alyftrek	Milder; often PS; reduced CFTR quantity
A455E	p.Ala455Glu	CF-causing	V (reduced quantity)	Missense	MONDO:0009061	Cystic fibrosis	~0.1%	Yes — ETI (Trikafta/Kaftrio), Alyftrek	Milder; PS; enriched in Northern Europe
R560T	p.Arg560Thr	CF-causing	III (gating)	Missense	MONDO:0009061	Cystic fibrosis	Rare	Yes — Ivacaftor (Kalydeco), ETI	Gating defect; modulator-responsive
S549N	p.Ser549Asn	CF-causing	III (gating)	Missense	MONDO:0009061	Cystic fibrosis	Rare	Yes — Ivacaftor (Kalydeco), ETI	Gating defect; modulator-responsive
R334W	p.Arg334Trp	CF-causing	IV (conductance)	Missense	MONDO:0009061	Cystic fibrosis	Rare	Yes — Ivacaftor (Kalydeco), ETI	Conductance defect; milder phenotype
5T allele	IVS8-5T (c.1210-12T[5])	Non-CF-causing (alone) / Context-dependent	V (splicing modifier)	Poly-T tract variant	MONDO:0010178	CBAVD from CFTR	25-45% of CBAVD chromosomes (vs ~5% general population)	Not applicable (CBAVD)	Most characteristic CBAVD variant; penetrance depends on TG repeat length (TG12/TG13 = high penetrance)
5T allele	IVS8-5T (c.1210-12T[5])	Non-CF-causing (alone) / Context-dependent	V (splicing modifier)	Poly-T tract variant	MONDO:7770004	CFTR-related disorder	Overrepresented in CFTR-RD	Not applicable (CFTR-RD)	Reduces exon 9 inclusion; reduced functional CFTR; contributes to single-organ CFTR dysfunction
5T allele	IVS8-5T (c.1210-12T[5])	Non-CF-causing (alone) / Context-dependent	V (splicing modifier)	Poly-T tract variant	MONDO:0100627	CRMS/CFSPID	Found in CRMS/CFSPID (with TG11 = low penetrance)	No (CRMS/CFSPID)	5T/TG11 haplotype is generally benign; 5T/TG12 or TG13 increases disease penetrance
5T allele	IVS8-5T (c.1210-12T[5])	Non-CF-causing (alone) / Context-dependent	V (splicing modifier)	Poly-T tract variant	MONDO:0008887	BESC1	Overrepresented in bronchiectasis	Unknown	May contribute to bronchiectasis through oligogenic mechanism with ENaC variants
TG12-5T	c.1210-12T[5];TG[12]	Context-dependent	V (splicing modifier)	Complex allele	MONDO:0010178	CBAVD from CFTR	High in CBAVD with 5T	Not applicable (CBAVD)	~80% penetrance for CBAVD; stronger splicing reduction than TG11-5T
TG13-5T	c.1210-12T[5];TG[13]	Context-dependent	V (splicing modifier)	Complex allele	MONDO:0010178	CBAVD from CFTR	High in CBAVD with 5T	Not applicable (CBAVD)	>80% penetrance for CBAVD; most severe splicing reduction
D1152H	p.Asp1152His	VVCC	IV-like (conductance)	Missense	MONDO:0010178	CBAVD from CFTR	Rare in CBAVD	Not applicable (CBAVD)	VVCC per CFTR2; found in CBAVD compound hets
D1152H	p.Asp1152His	VVCC	IV-like (conductance)	Missense	MONDO:0100627	CRMS/CFSPID	Common in CRMS/CFSPID	No (CRMS/CFSPID)	One of the most common VVCC variants triggering CRMS/CFSPID
D1152H	p.Asp1152His	VVCC	IV-like (conductance)	Missense	MONDO:7770004	CFTR-related disorder	Found in CFTR-RD	Not applicable (CFTR-RD)	Compound het with severe variant may cause single-organ CFTR-RD
D1270N	p.Asp1270Asn	VVCC	—	Missense	MONDO:0100627	CRMS/CFSPID	Found in CRMS/CFSPID	No (CRMS/CFSPID)	VVCC per CFTR2; common in newborn screening inconclusive diagnoses
L997F	p.Leu997Phe	VVCC	—	Missense	MONDO:0100627	CRMS/CFSPID	Found in CRMS/CFSPID	No (CRMS/CFSPID)	VVCC per CFTR2; reclassified from unknown significance in 2024 update
R74W	p.Arg74Trp	VVCC	—	Missense	MONDO:0010178	CBAVD from CFTR	Rare in CBAVD	Not applicable (CBAVD)	Mild/VVCC; found in CBAVD compound hets
R74W	p.Arg74Trp	VVCC	—	Missense	MONDO:0100627	CRMS/CFSPID	Found in CRMS/CFSPID	No (CRMS/CFSPID)	VVCC per CFTR2
R75Q	p.Arg75Gln	VVCC	—	Missense	MONDO:0100627	CRMS/CFSPID	Found in CRMS/CFSPID	No (CRMS/CFSPID)	VVCC per CFTR2
M470V	p.Met470Val	Non-CF-causing (polymorphism)	—	Missense (polymorphism)	MONDO:0010178	CBAVD from CFTR	Common polymorphism	Not applicable	Modulates 5T allele penetrance; M470V-5T haplotype affects CFTR protein maturation
M470V	p.Met470Val	Non-CF-causing (polymorphism)	—	Missense (polymorphism)	MONDO:0100627	CRMS/CFSPID	Common polymorphism	No	Modifies effect of other variants; not disease-causing on its own